Traditional and novel approaches to flavivirus vaccines.
暂无分享,去创建一个
F. Guirakhoo | T. Monath | D. Trent | Thomas P Monath | Konstantin V Pugachev | Farshad Guirakhoo | Dennis W Trent | K. Pugachev
[1] R. Garratt,et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. , 2002, Journal of molecular biology.
[2] B. Falgout,et al. Construction of a Full Length Infectious Clone for Dengue-1 Virus Western Pacific,74 Strain , 2004, Virus Genes.
[3] F. Heinz,et al. Proteolytic activation of tick-borne encephalitis virus by furin , 1997, Journal of virology.
[4] M. Bray,et al. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[5] S. Harrison,et al. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.
[6] H. Sumiyoshi,et al. Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates , 1992, Journal of virology.
[7] D. Vaughn,et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. , 2001, Vaccine.
[8] A. Pletnev. Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice. , 2001, Virology.
[9] C. Huang,et al. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine , 2000, Journal of Virology.
[10] J. Roehrig,et al. New Mouse Model for Dengue Virus Vaccine Testing , 1999, Journal of Virology.
[11] T. Monath,et al. Yellow fever: an update. , 2001, The Lancet. Infectious diseases.
[12] R. Karron,et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. , 2001, The American journal of tropical medicine and hygiene.
[13] M. Bray,et al. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[14] D. Vaughn,et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.
[15] F. Ennis,et al. Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes , 1989, Journal of virology.
[16] Gary J. Nabel,et al. New Generation Vaccines , 1990 .
[17] I. Tokimatsu,et al. Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence , 1998, Journal of Virology.
[18] R. Compans,et al. Regulation of the late events in flavivirus protein processing and maturation. , 1993, Virology.
[19] M. Bray,et al. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Bray,et al. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge , 1996, Journal of virology.
[21] D. Gubler,et al. Dengue and dengue hemorrhagic fever : Its history and resurgence as a global public health problem , 1997 .
[22] F. Guirakhoo,et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.
[23] A. Barrett,et al. Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. , 1998, Virology.
[24] M. Lobigs,et al. Mechanism of Virulence Attenuation of Glycosaminoglycan-Binding Variants of Japanese Encephalitis Virus and Murray Valley Encephalitis Virus , 2002, Journal of Virology.
[25] C. Mandl,et al. Capsid Protein C of Tick-Borne Encephalitis Virus Tolerates Large Internal Deletions and Is a Favorable Target for Attenuation of Virulence , 2002, Journal of Virology.
[26] B. Murphy,et al. Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice , 2001, Journal of Virology.
[27] A. Khromykh. Replicon-based vectors of positive strand RNA viruses. , 2000, Current opinion in molecular therapeutics.
[28] C. Rice,et al. Genetic Interaction of Flavivirus Nonstructural Proteins NS1 and NS4A as a Determinant of Replicase Function , 1999, Journal of Virology.
[29] C. Huang,et al. Development of New Vaccines against Dengue Fever and Japanese Encephalitis , 2001, Intervirology.
[30] B. Falgout,et al. Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys , 2002, Journal of Virology.
[31] Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice , 1995, Journal of virology.
[32] M. Bray,et al. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice , 1993, Journal of virology.
[33] P. McMinn,et al. Characterization of infectious Murray Valley encephalitis virus derived from a stably cloned genome-length cDNA. , 1999, The Journal of general virology.
[34] F. Ennis,et al. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones , 1994, Journal of virology.
[35] F. Ennis,et al. Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones , 1991, Journal of virology.
[36] M. Cetron,et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases , 2001, The Lancet.
[37] S. Punyagupta,et al. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[38] T. Tsai. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. , 2000, Vaccine.
[39] A. Rothman,et al. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. , 2002, Virology.
[40] A. Barrett. Current Status of Flavivirus Vaccines , 2001, Annals of the New York Academy of Sciences.
[41] J. An,et al. Development of a novel mouse model for dengue virus infection. , 1999, Virology.
[42] Peter F. Stadler,et al. Spontaneous and Engineered Deletions in the 3′ Noncoding Region of Tick-Borne Encephalitis Virus: Construction of Highly Attenuated Mutants of a Flavivirus , 1998, Journal of Virology.
[43] R. Andino,et al. Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases , 2000, Journal of Virology.
[44] E. Paoletti,et al. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. , 1991, Virology.
[45] F. Guirakhoo,et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. , 2001, Virology.
[46] F. Guirakhoo,et al. Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE) , 2001, Journal of Virology.
[47] J. Stephenson,et al. Defective adenoviruses as novel vaccines for the Flaviviridae. , 1998, Clinical and diagnostic virology.
[48] S. Halstead,et al. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. , 1989, Reviews of infectious diseases.
[49] E. Chungue,et al. Dengue virus inhibits human hematopoietic progenitor growth in vitro. , 1997, The Journal of infectious diseases.
[50] S. Vázquez,et al. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. , 2001, Virus research.
[51] T. Monath,et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases , 2001, The Lancet.
[52] A. Pletnev,et al. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Sabin. Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.
[54] C. Rice,et al. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation , 1997, Journal of virology.
[55] E. Paoletti,et al. Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones. , 1997, Virology.
[56] Gorbunov Ma,et al. [Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the "Immuno" firm]. , 1996 .
[57] R. Padmanabhan,et al. Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain). , 1995, Gene.
[58] A. Rothman,et al. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. , 2001, Vaccine.
[59] F. Guirakhoo,et al. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.
[60] H. Guzmán,et al. Immunization with Heterologous Flaviviruses Protective Against Fatal West Nile Encephalitis , 2002, Emerging infectious diseases.
[61] J. Sadoff,et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. , 1996, The Journal of infectious diseases.
[62] C. Mandl,et al. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH , 1995, Journal of virology.
[63] C. Lai,et al. Mutational analysis of the octapeptide sequence motif at the NS1-NS2A cleavage junction of dengue type 4 virus , 1992, Journal of virology.
[64] D. Vaughn,et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.
[65] C. Huang,et al. Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3 , 2000, Journal of Virology.
[66] E. Konishi,et al. Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles , 2001, Journal of Virology.
[67] T. Monath. Prospects for Development of a Vaccine against the West Nile Virus , 2001, Annals of the New York Academy of Sciences.
[68] M. Crabtree,et al. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. , 2000, The American journal of tropical medicine and hygiene.
[69] I. Kurane,et al. Immunity and immunopathology in dengue virus infections. , 1992, Seminars in immunology.
[70] F. Ennis,et al. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones , 1996, Journal of virology.
[71] C. Mandl,et al. Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr. , 1997, The Journal of general virology.
[72] A. Rothman,et al. Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes , 1993, Journal of virology.
[73] I. Zhulin,et al. Positional cloning of the murine flavivirus resistance gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[74] A. Helenius,et al. Folding and Dimerization of Tick-Borne Encephalitis Virus Envelope Proteins prM and E in the Endoplasmic Reticulum , 2002, Journal of Virology.
[75] A. Davidson,et al. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. , 1998, The Journal of general virology.
[76] A. Davidson,et al. Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication , 2001, Journal of Virology.
[77] A. Barrett,et al. Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys , 2000, Journal of Virology.
[78] D. Vaughn,et al. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[79] Robert H Levis,et al. Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast , 1997, Journal of virology.
[80] D. Trent,et al. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. , 1988, Vaccine.
[81] C. Kunz. Tick-borne encephalitis in Europe. , 1992, Acta Leidensia.
[82] P. Mason,et al. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. , 1995, Virology.
[83] E. G. Westaway,et al. Completion of Kunjin virus RNA sequence and recovery of an infectious RNA transcribed from stably cloned full-length cDNA , 1994, Journal of virology.
[84] J. H. Bauer,et al. THE TRANSMISSION OF YELLOW FEVER TO MACACUS RHESUS: PRELIMINARY NOTE , 1928 .
[85] T. Mizutani,et al. Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and far-eastern subtype strains. , 2001, Vaccine.
[86] R. Chanock,et al. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.
[87] E. Paoletti,et al. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. , 1994, Vaccine.
[88] Interaction of Yellow Fever Virus French Neurotropic Vaccine Strain with Monkey Brain: Characterization of Monkey Brain Membrane Receptor Escape Variants , 2000, Journal of Virology.
[89] Michael W. Parker,et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. , 1999, Science.
[90] D. Gubler,et al. Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.
[91] F. Guirakhoo,et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. , 2002, Vaccine.
[92] J. H. Strauss,et al. Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response , 2000, Journal of Virology.
[93] M. Bray,et al. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice , 1991, Journal of virology.
[94] R. Jou,et al. Screening of Protective Antigens of Japanese Encephalitis Virus by DNA Immunization: a Comparative Study with Conventional Viral Vaccines , 1999, Journal of Virology.
[95] C. Rice,et al. Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties , 1999, Journal of Virology.
[96] Tran Truong,et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. , 1996, The American journal of tropical medicine and hygiene.
[97] E. Marth,et al. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. , 2001, Vaccine.
[98] K. Hanley,et al. Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes , 2001, Journal of Virology.
[99] A. Pletnev,et al. Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome. , 1995, Virology.
[100] E. Paoletti,et al. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. , 1992, Virology.
[101] C. Mandl,et al. Sequence of the genes encoding the structural proteins of the low-virulence tick-borne flaviviruses Langat TP21 and Yelantsev. , 1991, Virology.
[102] C. Mandl,et al. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model , 1998, Nature Medicine.
[103] C. Rice,et al. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. , 1989, The New biologist.
[104] E. Konishi,et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. , 2000, Vaccine.
[105] A. Barrett,et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. , 1999, Vaccine.
[106] J. Roehrig,et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. , 1997, Virology.
[107] C. Rice,et al. Mutagenesis of the NS2B-NS3-Mediated Cleavage Site in the Flavivirus Capsid Protein Demonstrates a Requirement for Coordinated Processing , 1999, Journal of Virology.
[108] C. Mandl,et al. Adaptation of Tick-Borne Encephalitis Virus to BHK-21 Cells Results in the Formation of Multiple Heparan Sulfate Binding Sites in the Envelope Protein and Attenuation In Vivo , 2001, Journal of Virology.
[109] V. Yamshchikov,et al. A ‘minimal’ approach in design of flavivirus infectious DNA , 2001, Virus Research.
[110] P. Mason. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells , 1989, Virology.
[111] B. Murphy,et al. Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes , 2002, Journal of Virology.
[112] F. Guirakhoo,et al. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.
[113] M. Lobigs,et al. Substitutions at the Putative Receptor-Binding Site of an Encephalitic Flavivirus Alter Virulence and Host Cell Tropism and Reveal a Role for Glycosaminoglycans in Entry , 2000, Journal of Virology.
[114] T. Monath. Editorial: jennerian vaccination against West Nile virus. , 2002, The American journal of tropical medicine and hygiene.
[115] N. Kanesa-thasan,et al. Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. , 2002, The American journal of tropical medicine and hygiene.
[116] M. Bras,et al. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[117] A. Barrett,et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. , 1999, Virology.
[118] S. Halstead,et al. Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.
[119] D. Harrich,et al. Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8+ T-Cell Immunity , 2002, Journal of Virology.
[120] A. Pletnev,et al. Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. , 2000, Virology.
[121] R. Compans,et al. An infectious clone of the West Nile flavivirus. , 2001, Virology.
[122] R. Rico-Hesse,et al. Dengue Virus Structural Differences That Correlate with Pathogenesis , 1999, Journal of Virology.
[123] W. Rawlinson,et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine , 2001, The Lancet.
[124] C. Mandl,et al. Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E , 2001, Journal of Virology.
[125] T. Monath,et al. Dengue: the risk to developed and developing countries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.